A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

NCT07010497 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: irpagratinib

Sponsor

Asan Medical Center

Collaborators

[object Object]